GAS5 and non-small cell lung carcinoma: For example, a more advanced technique [62] may be needed to identify the specific site of ac4C modification on GAS5. Additionally, more cases are required to validate the efficiency of GAS5 as a biomarker for discriminating immunotherapy responders in NSCLC.